RSS

Sanofi

Major pharma player Sanofi has announced it will work with Google to establish a new virtual Innovation Lab in an effort to change the way future medicines and health services are delivered. Read more

News

Contract development and manufacturing organisation (CDMO) Recipharm has launched an integrated end-to-end inhalation offering for its customers. Read more

News

Global biopharmaceutical company, Sanofi, has reached a civil settlement with the US Securities and Exchange Commission (SEC), leading to a full resolution of the commission’s investigation into the company Read more

News

Sanofi Genzyme — specialty care global business unit of French pharma company Sanofi — has launched its multiple sclerosis (MS) drug in India, however, according to GlobalData, it should be cautious of fierce generic competition… Read more

News

Cablivi (caplacizumab) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of a rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP) Read more

News

Sanofi and Advent International have finalised negotiations for the acquisition of Zentiva — Sanofi’s European generics business — with both companies signing a Share Purchase Agreement worth €1.9 billion. Read more

News

Sanofi has acquired all outstanding shares, warrants and convertible bonds of Ablynx, following the expiration of the squeeze-out procedure. Read more

News

A brief round-up of some of the developments in the industry including a step in the right direction for oral insulin and an overview of Alantra Pharma’s Fast 50 index… Read more

Opinion

CDMO, Recipharm, has acquired Sanofi’s manufacturing centre and business located in Holmes Chapel, which will provide the company with a platform to take advantage of the growing respiratory drug market. Read more

News

Biopharmaceutical companies, Sanofi and Ablynx, have announced the successful results of the initial tender offer period for Sanofi to acquire outstanding shares of Ablynx. Read more

News

The US Food and Drug Administration (FDA) has accepted priority review of the biologics licence application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC)... Read more

News

The marketing authorisation application (MAA) for cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma (CSCC) has been accepted for review by the European Medicines Agency (EMA). Read more

News

The European Medicines Agency (EMA) has accepted for review an application for an add-on maintenance treatment in certain adults and adolescents (12 years and older) with inadequately controlled moderate-to-severe asthma, Dupixent (dupilumab). Read more

News

The European Medicines Agency (EMA) has accepted Sanofi’s regulatory submission for sotagliflozin, a potential treatment for type 1 diabetes, for review. Read more

News

Plans have been announced by Sanofi and Regeneron to make Praluent (alirocumab) more accessible and affordable for those patients with the greatest health risk and unmet need. Read more

News

Sanofi has completed its acquisition of Bioverativ for $105 per share in cash. As a result, Bioverativ is now a fully owned subsidiary of Sanofi. Read more

News

The US Food and Drug Administration (FDA) has accepted the supplemental biologics licence application (sBLA) of Dupixent (dupilumab) for review, revealed joint developers of the drug, Regeneron and Sanofi. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Sanofi has requested a review by the European Medicines Agency (EMA) of its treatment for sleeping sickness, fexinidazole, which it is developing in collaboration with the Drugs for Neglected Disease initiative (DNDi). Read more

News

Sanofi is to acquire all outstanding ordinary shares of a biopharmaceutical company that is currently focused on the discovery and development of Nanobodies, Ablynx. Read more

News